Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03256344
Title Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Amgen

triple-receptor negative breast cancer

colorectal cancer


Atezolizumab + Talimogene laherparepvec

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.